Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celldex Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing antibody-based therapeutics in immunology and mast cell-mediated disease. Its 8-K reports furnish financial results and corporate updates, including clinical and regulatory disclosures for barzolvolimab programs and other pipeline candidates, as well as material-event and capital-structure disclosures related to common stock financing.
Proxy materials describe annual stockholder voting matters, director elections, auditor ratification, executive compensation and equity incentive plan proposals. The filing record also identifies Celldex common stock, par value $.001, trading under CLDX on the Nasdaq Capital Market.
Celldex Therapeutics, Inc. reported that Sam Martin, its Senior Vice President and Chief Financial Officer, has informed the company of his plans to retire effective on or about March 31, 2027. Martin joined Celldex in April 2009 and has served as Chief Financial Officer since July 2017.
The company has begun a search for a new Chief Financial Officer. To support continuity, Martin intends to continue serving as CFO through March 31, 2027, or until an appointed successor begins serving in that role, to help ensure a smooth transition of his responsibilities.
Celldex Therapeutics reported that SVP & Chief Commercial Officer Teri L. Lawver received an incentive stock option grant for 90,000 shares of common stock. The option has an exercise price of $34.09 per share and expires on June 25, 2036.
According to the grant terms, 25% of the option vests on June 25, 2027, with the remaining portion vesting in equal quarterly installments over the following 12 quarters. Following this award, Lawver holds options covering 90,000 shares, reflecting a compensation-related equity incentive rather than an open-market transaction.
Celldex Therapeutics SVP & General Counsel Freddy A. Jimenez received a grant of 93,000 incentive stock options to buy Celldex common stock. The options carry an exercise price of $34.09 per share and were granted under the company’s 2021 Omnibus Equity Incentive Plan.
According to the vesting schedule, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters. The options expire on June 25, 2036, and this award brings his reported derivative holdings in this grant to 93,000 options.
Celldex Therapeutics, Inc. reported that SVP and Chief Medical Officer Diane C. Young received a grant of 57,000 Incentive Stock Options to buy common stock.
The options have an exercise price of $34.09 per share, were granted under the company’s 2021 Omnibus Equity Incentive Plan, and represent compensation rather than an open-market purchase.
According to the filing, 25% of the award will vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters, and the options will expire on June 25, 2036 if not exercised.
Celldex Therapeutics, Inc. reported that SVP of Regulatory Affairs Margo Heath-Chiozzi received an incentive stock option grant. The award covers 95,000 options to buy Celldex common stock at an exercise price of $34.09 per share, with 95,000 options held after the transaction.
According to the footnotes, the grant was made under the company’s 2021 Omnibus Equity Incentive Plan. Twenty-five percent of the options vest on June 25, 2027, and the remaining options vest in equal quarterly installments over the following 12 quarters, with the options expiring on June 25, 2036.
Celldex Therapeutics, Inc. reported that its SVP and CFO, Martin Samuel Bates, received an incentive stock option grant covering 93,000 shares of common stock. The option has an exercise price of $34.09 per share and was awarded under the company’s 2021 Omnibus Equity Incentive Plan.
According to the vesting schedule, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters, and the option expires on June 25, 2036. After this grant, Bates holds 93,000 incentive stock options directly.
Celldex Therapeutics, Inc. reported that SVP of Corporate Affairs & Administration Sarah Cavanaugh received a grant of incentive stock options. She was awarded options covering 95,000 shares of Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan.
Following this grant, she holds derivative securities for 95,000 underlying shares. The options have a long-term vesting schedule: 25% vest on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the subsequent 12 quarters, and they expire on June 25, 2036.
Celldex Therapeutics, Inc. reported that senior vice president and chief product development officer Elizabeth Crowley received a grant of options covering 100,000 shares of common stock. These incentive stock options have an exercise price of $34.09 per share and expire on June 25, 2036.
According to the disclosure, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters. After this grant, Crowley holds derivative securities representing 100,000 options directly.
Celldex Therapeutics, Inc. granted Senior Vice President and Chief Business Officer Ronald Pepin an incentive stock option covering 20,000 shares of common stock. The option has an exercise price of $34.09 per share and was issued under the company’s 2021 Omnibus Equity Incentive Plan.
According to the vesting schedule, 25% of the option vests on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the following 12 quarters. The option expires on June 25, 2036, and Pepin holds 20,000 derivative securities following this grant.
Celldex Therapeutics, Inc. Executive VP & Chief Scientific Officer Tibor Keler received an incentive stock option grant covering 115,000 shares of common stock. The option has an exercise price of $34.09 per share and expires on June 25, 2036.
According to the vesting terms, 25% of the option vests on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the following 12 quarters. After this grant, Keler holds options for 115,000 underlying shares directly.